Trials / Completed
CompletedNCT01078558
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
A Five Year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis or Psoriatic Arthritis Who Are Treated With HUMIRA (Adalimumab)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,940 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab).
Conditions
Timeline
- Start date
- 2004-05-13
- Primary completion
- 2018-01-11
- Completion
- 2018-01-11
- First posted
- 2010-03-02
- Last updated
- 2019-07-05
- Results posted
- 2019-07-05
Source: ClinicalTrials.gov record NCT01078558. Inclusion in this directory is not an endorsement.